(S)-(6-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol | 1263284-23-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: (S)-(6-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol
• 英文别名: [(2S)-6-bromo-2,3-dihydro-1,4-benzodioxin-2-yl]methanol
• CAS: 1263284-23-6
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: GJEZMJKQOBAYTM-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-溴-2-碘苯酚 在 sodium tetrahydroborate 、 C₇₃H₉₈OP₂ 、 palladium diacetate 、 potassium carbonate 、 caesium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 49.0h， 生成 (S)-(6-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol
  参考文献：
  名称：

  Pd-Catalyzed Asymmetric Intramolecular Aryl C–O Bond Formation with SDP(O) Ligand: Enantioselective Synthesis of (2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methanols

  摘要：

  Employing a chiral spirodiphosphine monoxide ligand with 1,1'-spirobiindane backbone (SDP(O)), a desymmetrization strategy of Pd-catalyzed intramolecular asymmetric aryl C-O coupling of 2-(2-halophenoxy)propane-1,3-diols, was developed. The SDP(O) ligand shows much better results than its SDP counterpart. The protocol provides an efficient and highly enantioselective method for the synthesis of 2-hydroxymethyl-1,4-benzodioxanes. Density functional theory studies provide a model that accounts for the origin of the enantioselectivity.

  DOI：

  10.1021/ol5036613

文献信息

• NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20150336943A1

  公开（公告）日：2015-11-26

  The present invention concerns benzodioxane-piperidine with general formula I: wherein notably: R1 represents one or more identical or different substituent(s) on the benzene ring, each independently representing a hydrogen or halogen atom, or a C 1-4 alkyl group, or a C 1-4 alkoxy group or a C 1-4 hydroxyalkyl group or a C 1-4 alkylcarbonyl or an alkoxycarbonyl group or an OH group or an SO2R group with R alkyl, or a CN group, or a CF3 group, or an OCF 3 group; n=1, 2 or 3; m=0 or 1, and R2 represents one or more identical or different substituent(s) on the oxazolidinone or morpholinone ring, each independently representing: a hydrogen atom, a C 1-4 alkyl group, or a C 1-4 alkoxy group, or a C 1-4 hydroxyalkyl group, or an alkylcarbonyl group, or an alkoxycarbonyl group, or an alkoxyphenyl group.

  本发明涉及具有通式I的苯二氧杂环戊二酮： 其中特别地： R1代表苯环上一个或多个相同或不同的取代基，每个独立地代表氢或卤素原子，或C1-4烷基，或C1-4烷氧基，或C1-4羟基烷基，或C1-4烷基羰基，或烷氧羰基，或OH基，或SO2R基，其中R是烷基，或CN基，或CF3基，或OCF3基； n=1, 2或3； m=0或1，以及 R2代表噁唑烷酮或吗啉酮环上一个或多个相同或不同的取代基，每个独立地代表： 氢原子，C1-4烷基，或C1-4烷氧基，或C1-4羟基烷基，或烷基羰基，或烷氧羰基，或烷氧基苯基。
• INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK
  申请人：PFIZER INC.

  公开号：US20130267493A1

  公开（公告）日：2013-10-10

  The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

  本发明涉及激活5'-腺苷单磷酸活化蛋白激酶（AMPK）的吲哚和吲唑化合物的化学式（I）。该发明还包括含有这些化合物的药物组合物以及治疗或预防通过激活AMPK改善的疾病、症状或疾病的方法。
• 不对称C-O偶联化合物的合成方法及其应用
  申请人：中国科学院广州生物医药与健康研究院

  公开号：CN105524039B

  公开（公告）日：2018-01-26

  本发明公开了一种不对称C‑O偶联化合物的合成方法及其应用，属于化学合成技术领域。该方法在催化剂、配体L的存在下，使式Ⅰ化合物反应生成式Ⅱ化合物。并且该方法无论对一级醇、二级醇或三级醇均有很好的作用，具有底物适用范围广、收率高、反应条件简单的优点，能够广泛的用于含手性芳醚及氧杂环结构的化合物合成中，如可用于制备奥沙莫唑坦、WB4101和派罗克生中，得到高光学纯度的产物。
• Indole and Indazole Compounds that Activate AMPK
  申请人：PFIZER INC.

  公开号：US20160016940A1

  公开（公告）日：2016-01-21

  The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

  本发明涉及式（I）的吲哚和吲唑化合物，其激活5′腺苷酸单磷酸激活蛋白激酶（AMPK）。本发明还包括含有这些化合物的药物组合物以及治疗或预防通过激活AMPK改善的疾病、状况或障碍的方法。
• Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Pharmacological Properties of (<i>S</i>)-<i>N</i>-[(6-Chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112)
  作者：David F. McComsey、Virginia L. Smith-Swintosky、Michael H. Parker、Douglas E. Brenneman、Ewa Malatynska、H. Steve White、Brian D. Klein、Karen S. Wilcox、Michael E. Milewski、Mark Herb、Michael F. A. Finley、Yi Liu、Mary Lou Lubin、Ning Qin、Allen B. Reitz、Bruce E. Maryanoff

  DOI：10.1021/jm400894u

  日期：2013.11.27

  Broad-spectrum anticonvulsants are of considerable interest as antiepileptic drugs, especially because of their potential for treating refractory patients. Such "neurostabilizers" have also been used to treat other neurological disorders, including migraine, bipolar disorder, and neuropathic pain. We synthesized a series of sulfamide derivatives (4-9, 10a-i, 11a, 11b, 12) and evaluated their anticonvulsant activity. Thus, we identified promising sulfamide 4 (JNJ-26489112) and explored its pharmacological properties. Compound 4 exhibited excellent anticonvulsant activity in rodents against audiogenic, electrically induced, and chemically induced seizures. Mechanistically, 4 inhibited voltage-gated Na+ channels and N-type Ca2+ channels and was effective as a K+ channel opener. The anticonvulsant profile of 4 suggests that it may be useful for treating multiple forms of epilepsy (generalized tonic-clonic, complex partial, absence seizures), including refractory (or pharmacoresistant) epilepsy, at dose levels that confer a good safety margin. On the basis of its pharmacology and other favorable characteristics, 4 was advanced into human clinical studies.